Our Biologics Production Facility (BPF) provides both early-phase (preclinical) and clinical (Phase 1) current Good Manufacturing Practice, or cGMP, manufacturing capabilities for a range of cellular-based products from eukaryotic and prokaryotic culture systems. These products include monoclonal antibodies, fusion proteins, conjugates, plasmids, viral vectors and peptide vaccines.
Our trained, qualified personnel conduct all manufacturing activities using approved written procedures in accordance with cGMP guidelines. We provide quality assurance oversight and review to ensure regulatory compliance and the safety of therapeutic products.
Virtual Tour | BPF Facility and Services | Clinical Vector Process Development
To start a collaboration with us, review our product management information or contact us at:
This virtual tour takes you inside the Therapeutic Products shared resource’s BPF to learn about the processes, facilities and equipment for producing high-quality biologics for preclinical studies and clinical trials. Highlights:
Go inside the BPF and learn about our work.
Our clinical vector process development team, directed by Dr. Hans-Peter Kiem, provides development, production and quality control of clinical-grade virus vectors that can be used to genetically modify primary cells for clinical protocols. The team currently uses lentiviral and AAV vectors primarily but is expanding to other viral vectors.
For more information about our clinical vector process development, contact Staff Scientist Dr. Megha Gupta.